Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01500525
Other study ID # MISP 40467
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 2011
Est. completion date April 2015

Study information

Verified date September 2021
Source Capital Institute of Pediatrics, China
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objectives: 1. To observe BDR distribution curve for Chinese non-asthmatic and controller-naïve asthmatic children from 4-12 years respectively 2. To compare BDR values between non-asthmatic group and controller-naïve asthmatic group, and analyze appropriate cut-off point value Background and rationale: According to the guidelines spirometry, including baseline forced expiratory volume in 1 second (FEV1) and the bronchodilator response (BDR) to short acting beta agonists (SABA), should be used in children as objective measures to establish the diagnosis and severity of bronchial asthma. Baseline FEV1 is usually in the normal range (greater than 80% predicted) in children, regardless of asthma severity, so several other objective measures have been suggested for diagnosis in children, including the response to a bronchodilator, which reflects airway reversibility. The current definition for a positive BDR is >12% reversibility. In the study carried out by Galant et al among 51 non-asthmatic children and 346 controller naïve asthmatic children between 4-17 years, the BDR value could achieve 12% in only 30.6% asthmatic children, across all severity. Also, in a study among 142 children between 5-10 years in UK, 9% increase in FEV1 after bronchodilator use was suggested as the cutoff point with good sensitivity and specificity. Difference between the proposed study to be carried out in our hospital and the one in Anhui Province is that we will tentatively calculate a BDR cutoff point by using receiver operating characteristic (ROC curve). And the cutoff point can be used as a reference indicator in asthma diagnosis and long-term management. The current BDR cutoff point of 12% that is not ideal for children can also be reflected in the clinical management. It has been shown that a persistent BDR value, even less than 12%, in asthmatic children suggests poor clinical outcome. In a 4 years study among 1041 asthmatic children in America carried out by Sharma et al, it showed that compared with individuals who had a BDR of 12% and 200ml, individuals who had a BDR of 10% had similar poor clinical outcomes (e.g. more hospital visits, more prednisone bursts, increased nocturnal awakenings, and missing more days of school). Same results were also obtained in Galant et al study among 679 asthmatic children among 5-18 years.


Description:

This is a prospective observational non-interventional clinical study. 1. Patient population: 300 non-asthmatic and 300 asthmatic children will be recruited. 1. Non-asthmatic group: healthy children from 4-12 years will be recruited from the Capital Institute of Pediatrics nearby schools Inclusion criteria: 1) Willingly attend this investigation 2) Chest physical tests are normal Exclusion criteria: 1) The child had been hospitalized for any severe respiratory condition 2) A physician had ever stated that the child had asthma, reactive airway diseases, or the child had taken antiasthma medications for symptoms 3) The child was diagnosed with congenital heart disease requiring surgery or medications for management 4) There are positive responses concerning other serious chest problems, chest surgery, chronic productive cough, recurrent intractable wheezing, and shortness of breath 5) The children can not finish the test that met American Thoracic Society criteria for preschool children in a maximum of 6 attempts and are unable to successfully complete post-bronchodilator (BD) spirometry 2. Asthmatic group: 4-12 years old asthmatic children will be recruited from the asthma clinic of the Capital Institute of Pediatrics Inclusion criteria: 1) Diagnose asthma by specialist of asthma (based on symptoms): criteria for the diagnosis of asthma made by the asthma specialist included a history of recurrent coughing, wheezing, or shortness of breath at rest or with exercise, symptomatic improvement after bronchodilator use, and exclusion of other diagnoses 2) Asymptomatic or mild symptomatic with no physical signs of wheeze at the time of testing 3) Not receiving controller medication 6 weeks prior to the initial evaluation 4) Willing to attend this investigation Exclusion criteria: 1. Using short β2 agonists within 6 hours 2. Using long acting β2 agonists within 24 hours 3. Can not finish the test that met American Thoracic Society criteria for preschool children in a maximum of 6 attempts and are unable to successfully complete post-bronchodilator spirometry. 2. Preparation before tests 1. Sign the consent form. 2. Fill the asthma severity form according to NEAPP guideline (asthmatic group). 3. Chest physical test, record on the form of test. 4. Standing height and weight will be measured. 5. Calculation of age: The date of test subtracts the date of birth. 3. Pulmonary function tests Standardized pulmonary function tests will be conducted. Contents of tests: Pre and post flow volume: forced volume vital capacity (FVC), FEV0.5, FEV1, FEV1/FVC ratio, PEF, forced expiratory flow 25 (FEF25), FEF50, FEF75, FEF25-75, forced expiratory time (FET), back-extrapolated volume (VBE), VBE/FVC. The BDR is based on pulmonary function measurements before and after administration of 2.5 mg albuterol by nebulizer. BDR is calculated as [(postbronchodilator FEV1- baseline FEV1)/baseline FEV1] x 100%. Study Procedures: 1. Spirometry preparation The spirometry was purchased from VIASYS Healthcare, Hochberg Germany (MasterScope). 1. Check: Before switch on, check the conjunction between flow sensor and the hand knob, ensure that the black compact is tightness. 2. Calibration: Before calibration, the room temperature, pressure, humidity should be tested and recorded and all of the parameter should be reconciled to BTPS condition. Using 2 liters scalar to calibrate flow. Every day do the even flow calibration. Every week do the flow linear calibration, include high, media and low flow these three different flow calibration. The variety should be less than 3%. The record of calibration should be printed, and the technician should be signed on it and save it. 2. Test method The training process is the same as Eigen H. et al (ref 8). The entire instruction and testing session for each child is strictly limited to 15 min, during which time children are instructed in the techniques of spirometry and performed at least three forced vital capacity maneuvers. A highly experienced children's pulmonary function technologist does the instruction for each child. At the time of testing, each child is given an explanation of the testing procedure individually and then tested using coaching techniques used in our pulmonary function laboratory in evaluating younger children. 3. Criteria for accepting Data (ATS/ERS 2005) The principles of spirometry quality control in preschool children are the same as for adults. 1. It is necessary to visually inspect the flow-volume and volume-time traces, and exclude maneuvers that are visibly inadequate. Maneuvers should be excluded if the flow-volume curve does not demonstrate a rapid rise to peak flow, or a smooth descending limb, with no evidence of cough or glottis closure. 2. The start of test should be quantified by calculating the VBE. Some investigators reported that more than 80% of the studied preschool population achieved a VBE of less than or equal to 80 ml or less than 12.5% of the FVC. Alternative criteria are presented, but these should be viewed as a guide to assist visual inspection, rather than as exclusion criteria. 3. The end of test should be quantified by reporting the point of cessation of flow. It is known that many preschool children cannot sustain forced expiration for 1 second, let alone the 6 seconds previously stipulated for adults (ref 9) , and the forced expired time should be reported but should not be used to exclude maneuvers. This pattern should not be misinterpreted as early termination (ref 10).


Recruitment information / eligibility

Status Completed
Enrollment 587
Est. completion date April 2015
Est. primary completion date January 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Years to 12 Years
Eligibility -Non-asthmatic group: healthy children from 4-12 years will be recruited from the Capital Institute of Pediatrics nearby schools Inclusion criteria: 1. Willingly attend this investigation 2. Chest physical tests are normal Exclusion criteria: 1. The child had been hospitalized for any severe respiratory condition 2. A physician had ever stated that the child had asthma, reactive airway diseases, or the child had taken antiasthma medications for symptoms 3. The child was diagnosed with congenital heart disease requiring surgery or medications for management 4. There are positive responses concerning other serious chest problems, chest surgery, chronic productive cough, recurrent intractable wheezing, and shortness of breath 5. The children can not finish the test that met American Thoracic Society criteria for preschool children in a maximum of 6 attempts and are unable to successfully complete post-bronchodilator (BD) spirometry - Asthmatic group: 4-12 years old asthmatic children will be recruited from the asthma clinic of the Capital Institute of Pediatrics Inclusion criteria: 1. Diagnose asthma by specialist of asthma (based on symptoms): criteria for the diagnosis of asthma made by the asthma specialist included a history of recurrent coughing, wheezing, or shortness of breath at rest or with exercise, symptomatic improvement after bronchodilator use, and exclusion of other diagnoses 2. Asymptomatic or mild symptomatic with no physical signs of wheeze at the time of testing 3. Not receiving controller medication 6 weeks prior to the initial evaluation 4. Willing to attend this investigation Exclusion criteria: 1. Using short ß2 agonists within 6 hours 2. Using long acting ß2 agonists within 24 hours 3. Can not finish the test that met American Thoracic Society criteria for preschool children in a maximum of 6 attempts and are unable to successfully complete post-bronchodilator spirometry.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Capital Institute of Pediatrics Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Capital Institute of Pediatrics, China Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

China, 

References & Publications (10)

American Thoracic Society; European Respiratory Society. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1463-71. — View Citation

Aurora P, Stocks J, Oliver C, Saunders C, Castle R, Chaziparasidis G, Bush A; London Cystic Fibrosis Collaboration. Quality control for spirometry in preschool children with and without lung disease. Am J Respir Crit Care Med. 2004 May 15;169(10):1152-9. — View Citation

Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med. 2004 Aug 15;170(4):426-32. Epub 2004 Jun 1. — View Citation

Dundas I, Chan EY, Bridge PD, McKenzie SA. Diagnostic accuracy of bronchodilator responsiveness in wheezy children. Thorax. 2005 Jan;60(1):13-6. — View Citation

Eigen H, Bieler H, Grant D, Christoph K, Terrill D, Heilman DK, Ambrosius WT, Tepper RS. Spirometric pulmonary function in healthy preschool children. Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):619-23. — View Citation

Galant SP, Morphew T, Amaro S, Liao O. Value of the bronchodilator response in assessing controller naïve asthmatic children. J Pediatr. 2007 Nov;151(5):457-62, 462.e1. — View Citation

Galant SP, Morphew T, Newcomb RL, Hioe K, Guijon O, Liao O. The relationship of the bronchodilator response phenotype to poor asthma control in children with normal spirometry. J Pediatr. 2011 Jun;158(6):953-959.e1. doi: 10.1016/j.jpeds.2010.11.029. Epub — View Citation

Kumar R, Wang B, Wang X, Chen C, Yang J, Fu L, Xu X. Bronchodilator responses in Chinese children from asthma index families and the general population. J Allergy Clin Immunol. 2006 Jun;117(6):1257-63. — View Citation

Naqvi M, Thyne S, Choudhry S, Tsai HJ, Navarro D, Castro RA, Nazario S, Rodriguez-Santana JR, Casal J, Torres A, Chapela R, Watson HG, Meade K, LeNoir M, Avila PC, Rodriguez-Cintron W, Burchard EG. Ethnic-specific differences in bronchodilator responsiven — View Citation

Sharma S, Litonjua AA, Tantisira KG, Fuhlbrigge AL, Szefler SJ, Strunk RC, Zeiger RS, Murphy AJ, Weiss ST; Childhood Asthma Management Program Research Group. Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma m — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bronchodilator Response in Asthmatic Children To observe bronchodilator response(BDR) distribution curve for Chinese non-asthmatic children from 4-12 years, BDR calculated as: (FEV 1 L post-bronchodilator - FEV 1 L pre-bronchodilator)/FEV 1 L pre-bronchodilator × 100%.
To observe BDR distribution curve for Chinese controller-naïve asthmatic children from 4-12 years
To compare BDR values between non-asthmatic group and controller-naïve asthmatic group, and analyze appropriate cut-off point value
3 years
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device